{"protocolSection": {"identificationModule": {"nctId": "NCT00605475", "orgStudyIdInfo": {"id": "CACZ885A2213"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes", "officialTitle": "A Multi Center, Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered Intravenously to Patients With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2012-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-12"}, "primaryCompletionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-18", "studyFirstSubmitQcDate": "2008-01-30", "studyFirstPostDateStruct": {"date": "2008-01-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-09-01", "resultsFirstSubmitQcDate": "2012-01-10", "resultsFirstPostDateStruct": {"date": "2012-02-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-01-10", "lastUpdatePostDateStruct": {"date": "2012-02-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose levels in response to an oral glucose tolerance test (OGTT)."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Type 2 Diabetes Mellitus", "Canakinumab", "ACZ885", "IL-1B antagonist", "metformin", "glycemic control", "insulin sensitivity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 231, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Canakinumab", "type": "EXPERIMENTAL", "description": "Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.\n\nAll participants were required to take a concomitant stable daily dose of metformin during the study.", "interventionNames": ["Drug: Canakinumab", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.\n\nAll participants were required to take a concomitant stable daily dose of metformin during the study.", "interventionNames": ["Drug: Placebo", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Canakinumab", "description": "Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.", "armGroupLabels": ["Canakinumab"], "otherNames": ["ACZ885"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants continued on their stable daily dose of metformin throughout the study", "armGroupLabels": ["Canakinumab", "Placebo"], "otherNames": ["Glucophage", "Glumetza"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline in Plasma HbA1c (Glycosylated Hemoglobin / Hemoglobin A1c)", "description": "Blood was drawn after an overnight fast to measure plasma HbA1c levels. End of Study is defined as the last Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)"}, {"measure": "Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT )", "description": "Mean Change in Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Glucose levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84"}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline in Plasma C-peptide AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test (OGTT)", "description": "Blood samples were drawn after an overnight fast and standard OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. C-peptide levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "Mean Change From Baseline in Plasma Insulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "Mean Change From Baseline in Plasma Proinsulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "Mean Change From Baseline in Plasma Glucagon AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Glucagon levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "Mean Change From Baseline in Peak Plasma Insulin/Proinsulin Level, Following Oral Glucose Tolerance Test (OGTT)", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin and proinsulin levels were measured. The insulin/proinsulin level was calculated by dividing the insulin level by the proinsulin level. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "Mean Insulin Secretion Rate ( ISR ) Relative to Glucose, 0 - 4 Hours", "description": "Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Mean ISR relative to glucose over 0-4 hours was calculated as follows:\n\nMean ISR relative to glucose = mean ISR / (glucose AUC/time interval). The mean ISR was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Day 28, Day 84"}, {"measure": "Mean Insulin Secretion Rate ( ISR ), 0 - 4 Hours", "description": "Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. The mean ISR over 0 - 4 hours was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Day 28, Day 84"}, {"measure": "Insulin Sensitivity Index ( ISI ) at Day 28, Day 48", "description": "Insulin sensitivity index (ISI) = 10000 / \\[fasting insulin (\u03bcIU/mL) x fasting glucose (mg/dL) x mean 2 hour insulin(\u03bcIU/mL) x mean 2 hour glucose (mg/dL)\\]1/2 where mean 2 hour insulin (or glucose) was defined as the insulin (or glucose)AUC(0-2 hr) divided by the time period (2 hr). In normal subjects the mean score \u00b1 SE is 0.366 \u00b1 0.029. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.", "timeFrame": "Day 28, Day 84"}, {"measure": "Insulinogenic Index, 0 - 30 Minutes", "description": "Insulinogenic index (0-30 min)\n\n* \\[Change in insulin (0-30 min) (\u03bcIU/mL)\\] / \\[Change in glucose (0-30 min) (mg/dL)\\]\n* \\[insulin (\u03bcIU/mL) at 30 min - insulin (\u03bcIU/mL) at 0 min\\] / \\[glucose (mg/dL) at 30 min - glucose (mg/dL) at 0 min), where insulin (or glucose) at 0 min was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data..", "timeFrame": "Day 28, Day 84"}, {"measure": "Mean Change From Baseline in Peak Plasma Glucose Following Oral Glucose Tolerance Test ( OGTT )", "description": "Mean Change in Peak Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Change from baseline assessed at Day 28 and 84. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "Mean Change From Baseline in Peak Plasma Fructosamine Level", "description": "Blood was drawn to measure change in plasma Fructosamine Level, from baseline to Day 14, 28, 56, 84, 126 and End of Study ( defined as the final available post-randomization assessment up to the last regularly scheduled visit at Day 168 \\[+/- 5\\]). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "timeFrame": "Baseline, Day 14, Day 28, Day 56, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)"}, {"measure": "Insulin Resistance as Measured by the Homeostatic Model Assessment (HOMA-IR)", "description": "Insulin Resistance is measured via the Homeostatic Model Assessment (HOMA-IR) using a computer to model insulin sensitivity. Insulin Sensitivity (HOMA-%S), where 100% is normal, is the reciprocal of insulin resistance (100/S%). HOMA IR = \\[fasting insulin (\u03bcU/mL)\\] x \\[fasting plasma glucose (mmol/L)\\] / 22.5 where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "\u03b2-cell Function as Measured by the Homeostatic Model Assessment (HOMA-\u03b2 )", "description": "\u03b2 cell function is measured by the Homeostatic Model Assessment(HOMA-\u03b2) using a computer to model \u03b2 cell function and insulin sensitivity . \u03b2 cell function is related to Insulin Sensitivity (HOMA-%S) and is the reciprocal of insulin resistance (100/S%). HOMA \u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\] where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.", "timeFrame": "Baseline, Day 28, Day 84"}, {"measure": "Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency", "description": "An adverse event is any unwanted event, whether related to study drug or not occurring during the study period. A Serious Adverse Event (SAE) is an event resulting in death, requiring or prolonging hospitalization, a congenital anomaly or other important medical event. AEs and SAEs were recorded at each visit.", "timeFrame": "Baseline to End of Study (56[+/-2] and 168 [+/- 5] days after dosing for Cohort 1 and Cohorts 2-4, respectively)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female patients aged 18 to 70 years, with type 2 diabetes mellitus (non-insulin dependent diabetes) for at least 6 months prior to study start\n* HbA1c between 7.0 and 9.5%\n* On stable dose metformin monotherapy\n* Stable body weight\n\nExclusion Criteria:\n\n* Poorly controlled type 2 diabetes (very low or very high blood sugar levels, or other indicators of poor control)\n* Acute infections prior to dosing\n* Patients with type 1 diabetes (insulin-dependent diabetes)\n* Taking diabetes medication (other than metformin)\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "NOVARTIS", "affiliation": "Novartis investigator site", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Arkansas Research Medical Testing", "city": "Little Rock", "state": "Arkansas", "zip": "72202", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Allied Research International - Cetero Research Miami", "city": "Miami", "state": "Florida", "zip": "33169", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Elite Research Institute Miami", "city": "Miami", "state": "Florida", "zip": "33169", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "International Research Center Towson", "city": "MD", "state": "Maryland", "zip": "21286", "country": "United States"}, {"facility": "Covance Clinical Research Unit Inc", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Charles River Clinical Services", "city": "NW Tacoma", "state": "Washington", "zip": "98418", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Novartis Investigator Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigator Site", "city": "Kiel", "country": "Germany", "geoPoint": {"lat": 54.32133, "lon": 10.13489}}, {"facility": "Novartis Investigator Site", "city": "Moenchengladbach", "country": "Germany", "geoPoint": {"lat": 51.18539, "lon": 6.44172}}, {"facility": "Novartis Investigator Site", "city": "Munich", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Novartis Investigative Site", "city": "Neuss", "country": "Germany", "geoPoint": {"lat": 51.19807, "lon": 6.68504}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "St. Petersberg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Cohort 1: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg"}, {"id": "FG001", "title": "Cohort 1: Placebo to Canakinumab 0.3 mg/kg", "description": "Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg"}, {"id": "FG002", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "FG003", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Placebo to Canakinumab 10 mg/kg"}, {"id": "FG004", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "FG005", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "FG006", "title": "Cohort 3 : Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "FG007", "title": "Cohort 3: Placebo Infusion", "description": "Single dose IV infusion of Placebo"}, {"id": "FG008", "title": "Cohort 4 : Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}, {"id": "FG009", "title": "Cohort 4: Placebo to Canakinumab 0.03 mg/kg", "description": "Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "45"}, {"groupId": "FG003", "numSubjects": "45"}, {"groupId": "FG004", "numSubjects": "25"}, {"groupId": "FG005", "numSubjects": "24"}, {"groupId": "FG006", "numSubjects": "23"}, {"groupId": "FG007", "numSubjects": "24"}, {"groupId": "FG008", "numSubjects": "20"}, {"groupId": "FG009", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "45"}, {"groupId": "FG003", "numSubjects": "45"}, {"groupId": "FG004", "numSubjects": "24"}, {"groupId": "FG005", "numSubjects": "22"}, {"groupId": "FG006", "numSubjects": "22"}, {"groupId": "FG007", "numSubjects": "24"}, {"groupId": "FG008", "numSubjects": "18"}, {"groupId": "FG009", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "2"}, {"groupId": "FG009", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Abnormal Laboratory Values", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Cohort 1: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg"}, {"id": "BG001", "title": "Cohort 1: Placebo to Canakinumab 0.3 mg/kg", "description": "Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg"}, {"id": "BG002", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "BG003", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Placebo to Canakinumab 10 mg/kg"}, {"id": "BG004", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "BG005", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "BG006", "title": "Cohort 3 : Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "BG007", "title": "Cohort 3: Placebo Infusion", "description": "Single dose IV infusion of Placebo"}, {"id": "BG008", "title": "Cohort 4 : Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}, {"id": "BG009", "title": "Cohort 4: Placebo to Canakinumab 0.03 mg/kg", "description": "Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg"}, {"id": "BG010", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "45"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "25"}, {"groupId": "BG005", "value": "24"}, {"groupId": "BG006", "value": "23"}, {"groupId": "BG007", "value": "24"}, {"groupId": "BG008", "value": "20"}, {"groupId": "BG009", "value": "10"}, {"groupId": "BG010", "value": "231"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53", "spread": "7.60"}, {"groupId": "BG001", "value": "52", "spread": "6.96"}, {"groupId": "BG002", "value": "57.1", "spread": "9.38"}, {"groupId": "BG003", "value": "57.5", "spread": "7.95"}, {"groupId": "BG004", "value": "53.9", "spread": "7.58"}, {"groupId": "BG005", "value": "55", "spread": "8.45"}, {"groupId": "BG006", "value": "55.1", "spread": "9.28"}, {"groupId": "BG007", "value": "54.7", "spread": "6.41"}, {"groupId": "BG008", "value": "53.9", "spread": "9.07"}, {"groupId": "BG009", "value": "56", "spread": "8.67"}, {"groupId": "BG010", "value": "54.6", "spread": "8.08"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "13"}, {"groupId": "BG005", "value": "17"}, {"groupId": "BG006", "value": "14"}, {"groupId": "BG007", "value": "16"}, {"groupId": "BG008", "value": "10"}, {"groupId": "BG009", "value": "2"}, {"groupId": "BG010", "value": "116"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "31"}, {"groupId": "BG004", "value": "12"}, {"groupId": "BG005", "value": "7"}, {"groupId": "BG006", "value": "9"}, {"groupId": "BG007", "value": "8"}, {"groupId": "BG008", "value": "10"}, {"groupId": "BG009", "value": "8"}, {"groupId": "BG010", "value": "115"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Mean Change From Baseline in Plasma C-peptide AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test (OGTT)", "description": "Blood samples were drawn after an overnight fast and standard OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. C-peptide levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol*h/L", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled Placebo of Cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 41, 41, 21, 23, 23, 31, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-335", "spread": "178.1"}, {"groupId": "OG001", "value": "-614", "spread": "178.1"}, {"groupId": "OG002", "value": "-492", "spread": "392.4"}, {"groupId": "OG003", "value": "-25", "spread": "367.6"}, {"groupId": "OG004", "value": "779", "spread": "367.6"}, {"groupId": "OG005", "value": "129", "spread": "319.4"}, {"groupId": "OG006", "value": "-553", "spread": "394.6"}]}]}, {"title": "Day 84 (n= 41, 43, 22, 24, 23, 32, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-601", "spread": "275.1"}, {"groupId": "OG001", "value": "-205", "spread": "268.6"}, {"groupId": "OG002", "value": "143", "spread": "386.5"}, {"groupId": "OG003", "value": "143", "spread": "361.1"}, {"groupId": "OG004", "value": "654", "spread": "368.9"}, {"groupId": "OG005", "value": "240", "spread": "316.0"}, {"groupId": "OG006", "value": "-939", "spread": "396.1"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Plasma HbA1c (Glycosylated Hemoglobin / Hemoglobin A1c)", "description": "Blood was drawn after an overnight fast to measure plasma HbA1c levels. End of Study is defined as the last Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, Day 28, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2:Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled Placebo of Cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 45, 45, 25, 23, 23, 34, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "0.057"}, {"groupId": "OG001", "value": "-0.26", "spread": "0.057"}, {"groupId": "OG002", "value": "-0.25", "spread": "0.065"}, {"groupId": "OG003", "value": "-0.30", "spread": "0.069"}, {"groupId": "OG004", "value": "-0.47", "spread": "0.068"}, {"groupId": "OG005", "value": "-0.24", "spread": "0.056"}, {"groupId": "OG006", "value": "-0.13", "spread": "0.073"}]}]}, {"title": "Day 84 (n= 44, 44, 25, 23, 23, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.46", "spread": "0.102"}, {"groupId": "OG001", "value": "-0.15", "spread": "0.105"}, {"groupId": "OG002", "value": "-0.04", "spread": "0.118"}, {"groupId": "OG003", "value": "-0.43", "spread": "0.124"}, {"groupId": "OG004", "value": "-0.59", "spread": "0.124"}, {"groupId": "OG005", "value": "0.32", "spread": "0.103"}, {"groupId": "OG006", "value": "-0.15", "spread": "0.132"}]}]}, {"title": "Day 126 (n= 45, 45, 21, 22, 23, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.29", "spread": "0.101"}, {"groupId": "OG001", "value": "-0.02", "spread": "0.101"}, {"groupId": "OG002", "value": "-0.08", "spread": "0.126"}, {"groupId": "OG003", "value": "-0.22", "spread": "0.123"}, {"groupId": "OG004", "value": "-0.40", "spread": "0.120"}, {"groupId": "OG005", "value": "-0.19", "spread": "0.101"}, {"groupId": "OG006", "value": "-0.11", "spread": "0.128"}]}]}, {"title": "End of Study (n= 43, 45, 24, 20, 21, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.26", "spread": "0.121"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.118"}, {"groupId": "OG002", "value": "0.27", "spread": "0.162"}, {"groupId": "OG003", "value": "-0.18", "spread": "0.178"}, {"groupId": "OG004", "value": "-0.39", "spread": "0.173"}, {"groupId": "OG005", "value": "-0.12", "spread": "0.138"}, {"groupId": "OG006", "value": "0.32", "spread": "0.177"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Plasma Insulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "\u00b5IU*h/mL", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 43, 45, 18, 21,16, 29, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.58", "spread": "6.156"}, {"groupId": "OG001", "value": "-14.25", "spread": "6.017"}, {"groupId": "OG002", "value": "-12.61", "spread": "8.173"}, {"groupId": "OG003", "value": "6.06", "spread": "7.477"}, {"groupId": "OG004", "value": "2.06", "spread": "8.494"}, {"groupId": "OG005", "value": "-8.26", "spread": "6.421"}, {"groupId": "OG006", "value": "-1.35", "spread": "7.637"}]}]}, {"title": "Day 84 (n= 43, 45, 22, 23, 19, 31, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.68", "spread": "11.054"}, {"groupId": "OG001", "value": "-6.97", "spread": "10.805"}, {"groupId": "OG002", "value": "-8.38", "spread": "9.095"}, {"groupId": "OG003", "value": "2.44", "spread": "8.673"}, {"groupId": "OG004", "value": "-6.65", "spread": "9.522"}, {"groupId": "OG005", "value": "-4.09", "spread": "7.592"}, {"groupId": "OG006", "value": "-10.52", "spread": "9.321"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Plasma Proinsulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol*h/L", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled placebo from cohort 3 and 4. ingle dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 36, 37, 22, 24, 21, 30, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.9", "spread": "8.37"}, {"groupId": "OG001", "value": "11.0", "spread": "8.25"}, {"groupId": "OG002", "value": "-13.7", "spread": "18.78"}, {"groupId": "OG003", "value": "-15.0", "spread": "17.64"}, {"groupId": "OG004", "value": "26.1", "spread": "18.81"}, {"groupId": "OG005", "value": "-16.2", "spread": "16.38"}, {"groupId": "OG006", "value": "-22.3", "spread": "19.25"}]}]}, {"title": "Day 84 (n= 36, 37, 23, 24, 21, 30, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.2", "spread": "10.95"}, {"groupId": "OG001", "value": "7.8", "spread": "10.79"}, {"groupId": "OG002", "value": "-25.8", "spread": "20.96"}, {"groupId": "OG003", "value": "-9.3", "spread": "20.33"}, {"groupId": "OG004", "value": "39.6", "spread": "21.68"}, {"groupId": "OG005", "value": "-25.9", "spread": "18.76"}, {"groupId": "OG006", "value": "-17.3", "spread": "22.17"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Plasma Glucagon AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Glucagon levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol*h/L", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4) Placebo Infusion", "description": "Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 41, 44, 22, 23, 23, 34, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.6", "spread": "2.30"}, {"groupId": "OG001", "value": "-4.0", "spread": "2.22"}, {"groupId": "OG002", "value": "-3.1", "spread": "3.43"}, {"groupId": "OG003", "value": "-3.7", "spread": "3.37"}, {"groupId": "OG004", "value": "-0.6", "spread": "3.36"}, {"groupId": "OG005", "value": "-2.7", "spread": "2.78"}, {"groupId": "OG006", "value": "-5.5", "spread": "3.60"}]}]}, {"title": "Day 84 (n= 42, 45, 23, 23, 23, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.7", "spread": "2.96"}, {"groupId": "OG001", "value": "-2.0", "spread": "2.86"}, {"groupId": "OG002", "value": "-1.0", "spread": "4.46"}, {"groupId": "OG003", "value": "-1.8", "spread": "4.48"}, {"groupId": "OG004", "value": "14.7", "spread": "4.46"}, {"groupId": "OG005", "value": "2.9", "spread": "3.74"}, {"groupId": "OG006", "value": "-4.0", "spread": "4.79"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT )", "description": "Mean Change in Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Glucose levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol*h/L", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3and 4): Placebo Infusion", "description": "Pooled Placebo of Cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "22"}, {"groupId": "OG005", "value": "33"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.7", "spread": "0.98"}, {"groupId": "OG001", "value": "-0.9", "spread": "0.96"}, {"groupId": "OG002", "value": "1.6", "spread": "1.66"}, {"groupId": "OG003", "value": "-0.9", "spread": "1.65"}, {"groupId": "OG004", "value": "-2.8", "spread": "1.73"}, {"groupId": "OG005", "value": "-2.3", "spread": "1.41"}, {"groupId": "OG006", "value": "-0.5", "spread": "1.81"}]}]}, {"title": "Day 84", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5", "spread": "1.26"}, {"groupId": "OG001", "value": "1.7", "spread": "1.24"}, {"groupId": "OG002", "value": "2.6", "spread": "1.72"}, {"groupId": "OG003", "value": "-2.8", "spread": "1.71"}, {"groupId": "OG004", "value": "-1.2", "spread": "1.79"}, {"groupId": "OG005", "value": "-2.8", "spread": "1.46"}, {"groupId": "OG006", "value": "-2.5", "spread": "1.88"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Peak Plasma Insulin/Proinsulin Level, Following Oral Glucose Tolerance Test (OGTT)", "description": "Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin and proinsulin levels were measured. The insulin/proinsulin level was calculated by dividing the insulin level by the proinsulin level. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/pmol", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4:Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 43, 45, 24, 24, 23, 34,20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.173", "spread": "0.3902"}, {"groupId": "OG001", "value": "-1.035", "spread": "0.3814"}, {"groupId": "OG002", "value": "0.160", "spread": "0.7996"}, {"groupId": "OG003", "value": "1.039", "spread": "0.7996"}, {"groupId": "OG004", "value": "0.293", "spread": "0.8169"}, {"groupId": "OG005", "value": "-0.031", "spread": "0.6755"}, {"groupId": "OG006", "value": "0.518", "spread": "0.8832"}]}]}, {"title": "Day 84 (n= 44, 44, 25, 24, 23, 34, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.852", "spread": "0.4890"}, {"groupId": "OG001", "value": "-0.688", "spread": "0.4890"}, {"groupId": "OG002", "value": "-0.689", "spread": "0.7973"}, {"groupId": "OG003", "value": "0.923", "spread": "0.8138"}, {"groupId": "OG004", "value": "0.250", "spread": "0.8313"}, {"groupId": "OG005", "value": "0.682", "spread": "0.6871"}, {"groupId": "OG006", "value": "-0.046", "spread": "0.8991"}]}]}]}, {"type": "SECONDARY", "title": "Mean Insulin Secretion Rate ( ISR ) Relative to Glucose, 0 - 4 Hours", "description": "Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Mean ISR relative to glucose over 0-4 hours was calculated as follows:\n\nMean ISR relative to glucose = mean ISR / (glucose AUC/time interval). The mean ISR was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/min/m^2/mmol/L", "timeFrame": "Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4) Placebo Infusion", "description": "Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 41, 43, 23, 23, 22, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.4", "spread": "0.53"}, {"groupId": "OG001", "value": "18.0", "spread": "0.52"}, {"groupId": "OG002", "value": "14.5", "spread": "1.03"}, {"groupId": "OG003", "value": "17.1", "spread": "1.03"}, {"groupId": "OG004", "value": "19.1", "spread": "1.05"}, {"groupId": "OG005", "value": "18.5", "spread": "0.86"}, {"groupId": "OG006", "value": "16.1", "spread": "1.10"}]}]}, {"title": "Day 84 (n= 42, 43, 24, 24, 22, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "18.5", "spread": "1.00"}, {"groupId": "OG001", "value": "19.0", "spread": "0.99"}, {"groupId": "OG002", "value": "16.8", "spread": "1.13"}, {"groupId": "OG003", "value": "18.4", "spread": "1.13"}, {"groupId": "OG004", "value": "18.5", "spread": "1.18"}, {"groupId": "OG005", "value": "18.9", "spread": "0.96"}, {"groupId": "OG006", "value": "15.9", "spread": "1.24"}]}]}]}, {"type": "SECONDARY", "title": "Mean Insulin Secretion Rate ( ISR ), 0 - 4 Hours", "description": "Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. The mean ISR over 0 - 4 hours was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/min/m^2", "timeFrame": "Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4) Placebo Infusion", "description": "Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 42, 43, 23, 23, 23, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "255", "spread": "6.4"}, {"groupId": "OG001", "value": "246", "spread": "6.3"}, {"groupId": "OG002", "value": "207", "spread": "13.1"}, {"groupId": "OG003", "value": "231", "spread": "13.0"}, {"groupId": "OG004", "value": "262", "spread": "13.0"}, {"groupId": "OG005", "value": "234", "spread": "10.9"}, {"groupId": "OG006", "value": "212", "spread": "13.9"}]}]}, {"title": "Day 84 (n= 43, 43, 25, 24, 23, 34, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "248", "spread": "9.3"}, {"groupId": "OG001", "value": "259", "spread": "9.3"}, {"groupId": "OG002", "value": "234", "spread": "12.6"}, {"groupId": "OG003", "value": "234", "spread": "12.7"}, {"groupId": "OG004", "value": "254", "spread": "13.0"}, {"groupId": "OG005", "value": "239", "spread": "10.8"}, {"groupId": "OG006", "value": "197", "spread": "13.9"}]}]}]}, {"type": "SECONDARY", "title": "Insulin Sensitivity Index ( ISI ) at Day 28, Day 48", "description": "Insulin sensitivity index (ISI) = 10000 / \\[fasting insulin (\u03bcIU/mL) x fasting glucose (mg/dL) x mean 2 hour insulin(\u03bcIU/mL) x mean 2 hour glucose (mg/dL)\\]1/2 where mean 2 hour insulin (or glucose) was defined as the insulin (or glucose)AUC(0-2 hr) divided by the time period (2 hr). In normal subjects the mean score \u00b1 SE is 0.366 \u00b1 0.029. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled placebo of cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 40, 40, 12, 17, 14, 22, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.91", "spread": "0.049"}, {"groupId": "OG001", "value": "2.63", "spread": "0.049"}, {"groupId": "OG002", "value": "3.13", "spread": "0.093"}, {"groupId": "OG003", "value": "2.96", "spread": "0.077"}, {"groupId": "OG004", "value": "3.57", "spread": "0.083"}, {"groupId": "OG005", "value": "3.77", "spread": "0.068"}, {"groupId": "OG006", "value": "3.39", "spread": "0.071"}]}]}, {"title": "Day 84 (n= 39, 43, 13, 20, 14, 27, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.96", "spread": "0.043"}, {"groupId": "OG001", "value": "2.80", "spread": "0.041"}, {"groupId": "OG002", "value": "3.34", "spread": "0.109"}, {"groupId": "OG003", "value": "3.04", "spread": "0.085"}, {"groupId": "OG004", "value": "2.99", "spread": "0.101"}, {"groupId": "OG005", "value": "3.63", "spread": "0.074"}, {"groupId": "OG006", "value": "3.70", "spread": "0.086"}]}]}]}, {"type": "SECONDARY", "title": "Insulinogenic Index, 0 - 30 Minutes", "description": "Insulinogenic index (0-30 min)\n\n* \\[Change in insulin (0-30 min) (\u03bcIU/mL)\\] / \\[Change in glucose (0-30 min) (mg/dL)\\]\n* \\[insulin (\u03bcIU/mL) at 30 min - insulin (\u03bcIU/mL) at 0 min\\] / \\[glucose (mg/dL) at 30 min - glucose (mg/dL) at 0 min), where insulin (or glucose) at 0 min was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data..", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n=44, 44, 17, 23 17, 32, 18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.174", "spread": "0.0754"}, {"groupId": "OG001", "value": "0.140", "spread": "0.0754"}, {"groupId": "OG002", "value": "0.090", "spread": "0.1995"}, {"groupId": "OG003", "value": "0.105", "spread": "0.1735"}, {"groupId": "OG004", "value": "0.139", "spread": "0.1991"}, {"groupId": "OG005", "value": "0.102", "spread": "0.1464"}, {"groupId": "OG006", "value": "0.137", "spread": "0.1942"}]}]}, {"title": "Day 84 (n=43, 44, 17, 24, 20, 31, 17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.157", "spread": "0.0987"}, {"groupId": "OG001", "value": "0.134", "spread": "0.0976"}, {"groupId": "OG002", "value": "0.092", "spread": "0.1928"}, {"groupId": "OG003", "value": "0.098", "spread": "0.1651"}, {"groupId": "OG004", "value": "0.111", "spread": "0.1777"}, {"groupId": "OG005", "value": "0.124", "spread": "0.1445"}, {"groupId": "OG006", "value": "0.121", "spread": "0.1937"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Peak Plasma Glucose Following Oral Glucose Tolerance Test ( OGTT )", "description": "Mean Change in Peak Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Change from baseline assessed at Day 28 and 84. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3:Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3:Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4) Placebo Infusion", "description": "Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4:Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "33"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "0.30"}, {"groupId": "OG001", "value": "0.0", "spread": "0.30"}, {"groupId": "OG002", "value": "0.2", "spread": "0.55"}, {"groupId": "OG003", "value": "-0.2", "spread": "0.55"}, {"groupId": "OG004", "value": "-0.8", "spread": "0.57"}, {"groupId": "OG005", "value": "-1.0", "spread": "0.47"}, {"groupId": "OG006", "value": "0.1", "spread": "0.61"}]}]}, {"title": "Day 84", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.38"}, {"groupId": "OG001", "value": "0.6", "spread": "0.37"}, {"groupId": "OG002", "value": "0.2", "spread": "0.58"}, {"groupId": "OG003", "value": "-0.7", "spread": "0.58"}, {"groupId": "OG004", "value": "0.3", "spread": "0.60"}, {"groupId": "OG005", "value": "-0.9", "spread": "0.50"}, {"groupId": "OG006", "value": "-0.3", "spread": "0.64"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Peak Plasma Fructosamine Level", "description": "Blood was drawn to measure change in plasma Fructosamine Level, from baseline to Day 14, 28, 56, 84, 126 and End of Study ( defined as the final available post-randomization assessment up to the last regularly scheduled visit at Day 168 \\[+/- 5\\]). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "\u00b5mol/L", "timeFrame": "Baseline, Day 14, Day 28, Day 56, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"title": "Day 14 (n= 44, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.8", "spread": "3.0"}, {"groupId": "OG001", "value": "-0.7", "spread": "2.97"}]}]}, {"title": "Day 28 (n= 45, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.2", "spread": "3.72"}, {"groupId": "OG001", "value": "-13.9", "spread": "3.72"}]}]}, {"title": "Day 56 (n= 43, 44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "spread": "4.88"}, {"groupId": "OG001", "value": "-0.9", "spread": "4.82"}]}]}, {"title": "Day 84 (n= 44, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.6", "spread": "4.71"}, {"groupId": "OG001", "value": "-12.1", "spread": "4.65"}]}]}, {"title": "Day 126 (n= 45, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.6", "spread": "4.84"}, {"groupId": "OG001", "value": "-1.1", "spread": "4.84"}]}]}, {"title": "End of Study (n = 45, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.2", "spread": "7.25"}, {"groupId": "OG001", "value": "4.9", "spread": "7.25"}]}]}]}, {"type": "SECONDARY", "title": "Insulin Resistance as Measured by the Homeostatic Model Assessment (HOMA-IR)", "description": "Insulin Resistance is measured via the Homeostatic Model Assessment (HOMA-IR) using a computer to model insulin sensitivity. Insulin Sensitivity (HOMA-%S), where 100% is normal, is the reciprocal of insulin resistance (100/S%). HOMA IR = \\[fasting insulin (\u03bcU/mL)\\] x \\[fasting plasma glucose (mmol/L)\\] / 22.5 where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4): Placebo Infusion", "description": "Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 44, 45, 24, 24, 22, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.30", "spread": "0.059"}, {"groupId": "OG001", "value": "3.74", "spread": "0.058"}, {"groupId": "OG002", "value": "4.03", "spread": "0.092"}, {"groupId": "OG003", "value": "3.34", "spread": "0.091"}, {"groupId": "OG004", "value": "3.31", "spread": "0.095"}, {"groupId": "OG005", "value": "3.25", "spread": "0.078"}, {"groupId": "OG006", "value": "3.31", "spread": "0.101"}]}]}, {"title": "Day 84 (n= 44, 45, 24, 24, 23, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.37", "spread": "0.054"}, {"groupId": "OG001", "value": "3.62", "spread": "0.053"}, {"groupId": "OG002", "value": "3.87", "spread": "0.103"}, {"groupId": "OG003", "value": "3.43", "spread": "0.101"}, {"groupId": "OG004", "value": "4.09", "spread": "0.103"}, {"groupId": "OG005", "value": "3.06", "spread": "0.087"}, {"groupId": "OG006", "value": "2.94", "spread": "0.113"}]}]}]}, {"type": "SECONDARY", "title": "\u03b2-cell Function as Measured by the Homeostatic Model Assessment (HOMA-\u03b2 )", "description": "\u03b2 cell function is measured by the Homeostatic Model Assessment(HOMA-\u03b2) using a computer to model \u03b2 cell function and insulin sensitivity . \u03b2 cell function is related to Insulin Sensitivity (HOMA-%S) and is the reciprocal of insulin resistance (100/S%). HOMA \u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\] where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.", "populationDescription": "All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent \u03b2-cell Function", "timeFrame": "Baseline, Day 28, Day 84", "groups": [{"id": "OG000", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG001", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG002", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG003", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG005", "title": "Pooled (Cohort 3 and 4) : Placebo Infusion", "description": "Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo"}, {"id": "OG006", "title": "Cohort 4: Anakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "23"}, {"groupId": "OG005", "value": "34"}, {"groupId": "OG006", "value": "20"}]}], "classes": [{"title": "Day 28 (n= 44, 45, 24, 24, 22, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.2", "spread": "0.05"}, {"groupId": "OG001", "value": "35.9", "spread": "0.05"}, {"groupId": "OG002", "value": "38.1", "spread": "0.10"}, {"groupId": "OG003", "value": "38.2", "spread": "0.10"}, {"groupId": "OG004", "value": "42.0", "spread": "0.11"}, {"groupId": "OG005", "value": "37.9", "spread": "0.09"}, {"groupId": "OG006", "value": "38.3", "spread": "0.11"}]}]}, {"title": "Day 84 (n= 44, 45, 24, 24, 23, 33, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.6", "spread": "0.06"}, {"groupId": "OG001", "value": "34.3", "spread": "0.06"}, {"groupId": "OG002", "value": "34.6", "spread": "0.10"}, {"groupId": "OG003", "value": "37.6", "spread": "0.10"}, {"groupId": "OG004", "value": "43.3", "spread": "0.10"}, {"groupId": "OG005", "value": "37.2", "spread": "0.09"}, {"groupId": "OG006", "value": "33.7", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency", "description": "An adverse event is any unwanted event, whether related to study drug or not occurring during the study period. A Serious Adverse Event (SAE) is an event resulting in death, requiring or prolonging hospitalization, a congenital anomaly or other important medical event. AEs and SAEs were recorded at each visit.", "populationDescription": "All randomized participants who received study medication were included in the Safety Analysis", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to End of Study (56[+/-2] and 168 [+/- 5] days after dosing for Cohort 1 and Cohorts 2-4, respectively)", "groups": [{"id": "OG000", "title": "Cohort 1: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg"}, {"id": "OG001", "title": "Cohort 1: Placebo to Canakinumab 0.3 mg/kg", "description": "Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg"}, {"id": "OG002", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg"}, {"id": "OG003", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Placebo to Canakinumab 10 mg/kg"}, {"id": "OG004", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg"}, {"id": "OG005", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg"}, {"id": "OG006", "title": "Cohort 3 : Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg"}, {"id": "OG007", "title": "Cohort 3: Placebo Infusion", "description": "Single dose IV infusion of Placebo"}, {"id": "OG008", "title": "Cohort 4 : Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg"}, {"id": "OG009", "title": "Cohort 4: Placebo to Canakinumab 0.03 mg/kg", "description": "Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "45"}, {"groupId": "OG003", "value": "45"}, {"groupId": "OG004", "value": "25"}, {"groupId": "OG005", "value": "24"}, {"groupId": "OG006", "value": "23"}, {"groupId": "OG007", "value": "24"}, {"groupId": "OG008", "value": "20"}, {"groupId": "OG009", "value": "10"}]}], "classes": [{"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}]}]}, {"title": "Adverse Events Above 5 % Frequency", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "4"}, {"groupId": "OG005", "value": "4"}, {"groupId": "OG006", "value": "2"}, {"groupId": "OG007", "value": "6"}, {"groupId": "OG008", "value": "10"}, {"groupId": "OG009", "value": "2"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Cohort 1: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 1, "otherNumAtRisk": 10}, {"id": "EG001", "title": "Cohort 1: Placebo to Canakinumab 0.3 mg/kg", "description": "Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 2, "otherNumAtRisk": 5}, {"id": "EG002", "title": "Cohort 2: Canakinumab Infusion 10 mg/kg", "description": "Single dose IV infusion of Canakinumab 10 mg/kg", "seriousNumAffected": 1, "seriousNumAtRisk": 45, "otherNumAffected": 9, "otherNumAtRisk": 45}, {"id": "EG003", "title": "Cohort 2: Placebo to Canakinumab 10 mg/kg", "description": "Single dose IV infusion of Placebo to Canakinumab 10 mg/kg", "seriousNumAffected": 2, "seriousNumAtRisk": 45, "otherNumAffected": 6, "otherNumAtRisk": 45}, {"id": "EG004", "title": "Cohort 3: Canakinumab Infusion 0.1 mg/kg", "description": "Single dose IV infusion Canakinumab 0.1 mg/kg", "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 4, "otherNumAtRisk": 25}, {"id": "EG005", "title": "Cohort 3: Canakinumab Infusion 0.3 mg/kg", "description": "Single dose IV infusion of Canakinumab 0.3 mg/kg", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 4, "otherNumAtRisk": 24}, {"id": "EG006", "title": "Cohort 3 : Canakinumab Infusion 1.5 mg/kg", "description": "Single dose IV infusion of canakinumab 1.5 mg/kg", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 2, "otherNumAtRisk": 23}, {"id": "EG007", "title": "Cohort 3: Placebo Infusion", "description": "Single dose IV infusion of Placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 6, "otherNumAtRisk": 24}, {"id": "EG008", "title": "Cohort 4 : Canakinumab Injection 0.03 mg/kg", "description": "Single dose IV injection of Canakinumab 0.03 mg/kg", "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 10, "otherNumAtRisk": 20}, {"id": "EG009", "title": "Cohort 4: Placebo to Canakinumab 0.03 mg/kg", "description": "Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 2, "otherNumAtRisk": 10}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Intestinal polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}], "otherEvents": [{"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 10}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Ocular hyperaemia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Visual acuity reduced", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 10}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG007", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 10}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary, however, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data ( i.e., data from all sites ) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778 8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}